Vanguard Fiduciary Trust
LGND icon

Vanguard Fiduciary Trust’s Ligand Pharmaceuticals LGND Stock Holding History

Vanguard Fiduciary Trust’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.2M Buy
142,926
+15,027
+12% +$3.54M 0.01% 928
2026
Q1 		$25.5M Buy
+127,899
New +$25.3M 0.01% 1173

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust's LGND Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Ligand Pharmaceuticals (LGND) stake by 12% in Q2 2026, buying an estimated $3.54M and bringing the position to 142,926 shares worth $45.2M. The position accounts for 0.01% of the portfolio, ranked #928.

Vanguard Fiduciary Trust first reported a position in LGND in Q1 2026 and has held it in 2 quarters since. 412 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Vanguard Fiduciary Trust held 142,926 shares of Ligand Pharmaceuticals worth $45.2M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 15,027 Ligand Pharmaceuticals shares in Q2 2026, an estimated $3.54M.
  • Ligand Pharmaceuticals made up 0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #928 holding.
  • Vanguard Fiduciary Trust first reported a position in Ligand Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 412 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.